Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
  2. >
  3. Stock
  4. >
  5. CHE
  6. >
  7. Earnings
stocks logo

CHE Earnings

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings

Earning Analysis

Welcome to our in-depth analysis of Chemed Corp(CHE) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Chemed Corp earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.

Earnings Forecast

Revenue
EPS
Currency: USD
Actual
Estimate

Surprise Analysis

Name
EPS
Revenue
Price Reaction
Fiscal QuarterEarning DateTimeEstimateActualSurprise%EstimateActualSurprise%1D5D
Fiscal Quarter
Earning Date
Time
Estimate
Actual
Surprise%
Estimate
Actual
Surprise%
1D
5D
FY2025Q32025-10-28After Hours5.365.27-1.68626.04M624.90M-0.18+6.06+0.40
FY2025Q22025-07-29After Hours4.914.27-13.03623.93M618.80M-0.82-10.36-8.90
FY2025Q12025-04-23After Hours5.555.63+1.44641.78M646.94M+0.80-6.61-1.79
FY2024Q42025-02-26After Hours6.786.83+0.74636.10M639.99M+0.61+7.39+9.05
FY2024Q32024-10-29After Hours5.765.64-2.08612.22M606.18M-0.99-12.14-12.57
FY2024Q22024-07-24-5.145.01-2.53599.20M595.88M-0.55+1.14+4.59
FY2024Q12024-04-24-5.094.68-8.06591.10M589.23M-0.32+0.23-7.87
FY2023Q42024-02-27-6.256.60+5.60586.64M585.91M-0.12-0.31+5.61
FY2023Q32023-10-25-4.925.32+8.13558.42M564.53M+1.10-0.02+10.95
FY2023Q22023-07-26-5.094.71-7.47562.54M553.82M-1.55+0.04-8.02
Intellectia AI SwingMax
Intellectia AI SwingMax

CHE Earnings Analysis

Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Chemed Corp reported performance for FY2025Q3, announced on 2025-10-28. The company achieved an EPS of 5.27, compared to analyst estimates of 5.36 by -1.68% . Revenue for the quarter reached 624.90M compared to expectations of 626.04M by -0.18% .
The stock price reacted with a 6.06% one-day change and a 0.40% five-day change following the earnings release. These movements reflect market reaction in Chemed Corp growth trajectory and strategic initiatives.

CHE Earnings Forecast

Looking ahead, Chemed Corp(CHE) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 658.97M and an EPS of 7.07.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Downward by -0.01%, while EPS estimates have been Revise Upward by 0.27%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Upward by 0.11% . These revisions correlate with a -8.88% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Chemed Corp long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.

Estimate Revision

The chart shows the correlation between CHE's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.01%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.27%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Upward
up Image
+0.11%
In Past 3 Month
Stock Price
Go Down
down Image
-8.88%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:2.55B
--
EPS Estimate-Annual FY 2025:22.19
—
Stock Price424.30
Financial AI Agent
Financial AI Agent

CHE Revenue and EPS Performance: A Historical Perspective

Chemed Corp revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q3 (2025-10-28,After Hours):
EPS: 5.27 (Actual) vs.5.36 (Estimate) (-1.68%)
Revenue: 624.90M (Actual) vs. 626.04M (Estimate) (-0.18%)
Price Reaction: 6.06%(1-Day), 0.40%(5-Day)
FY2025Q2 (2025-07-29,After Hours):
EPS: 4.27 (Actual) vs.4.91 (Estimate) (-13.03%)
Revenue: 618.80M (Actual) vs. 623.93M (Estimate) (-0.82%)
Price Reaction: -10.36%(1-Day), -8.90%(5-Day)
FY2025Q1 (2025-04-23,After Hours):
EPS: 5.63 (Actual) vs.5.55 (Estimate) (1.44%)
Revenue: 646.94M (Actual) vs. 641.78M (Estimate) (0.80%)
Price Reaction: -6.61%(1-Day), -1.79%(5-Day)
Earnings Reaction
The chart below shows how CHE performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CHE sees a -1.34% change in stock price 10 days leading up to the earnings, and a +0.61% change 10 days following the report. On the earnings day itself, the stock moves by +0.16%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed 6.06% on the day following the earnings release and then changed by 1.50% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
AI Stock Picker
AI Stock Picker

Transcript Summary

Chemed Corp (CHE) Q3 2025 Earnings Call Summary
Neutral
2025-10-29
The earnings call highlights mixed results: strong revenue growth projections for VITAS in 2025, but declining EBITDA margins in both VITAS and Roto-Rooter. Management's optimism about future margin improvements and revenue growth is offset by current financial declines and vague guidance for 2026. The Q&A session reveals concerns about elevated DSO and unclear responses on strategic improvements. Overall, these factors suggest a neutral sentiment, with no strong catalysts for significant stock price movement in the next two weeks.
Chemed Corp (CHE) Q2 2025 Earnings Call Summary
Neutral
2025-07-30
The earnings call presents a mixed picture. Positive elements include VITAS's revenue growth and strategic acquisitions, while negative aspects involve declining Roto-Rooter EBITDA and margin concerns. The Q&A session revealed management's efforts to address issues but also highlighted uncertainties, particularly with Roto-Rooter and VITAS admissions. The lack of detailed guidance and unclear responses create uncertainty, balancing the positive impact of share buybacks and strategic focus. Overall, the sentiment is neutral as the positive and negative factors counterbalance each other, leading to an expected stock price movement within the -2% to 2% range.
Chemed Corp (CHE) Q1 2025 Earnings Call Summary
Positive
2025-04-24
The earnings call reveals strong financial performance for VITAS and Roto-Rooter, with significant revenue and EBITDA growth. Despite challenges like Medicare Cap and competitive pressures, the company has effective strategies to mitigate these risks. The absence of a share buyback program and slightly declining EBITDA margin for Roto-Rooter are minor concerns. The Q&A indicates management's confidence in handling cap issues and cash flow dynamics. Overall, the positive financial metrics and strategic initiatives outweigh the risks, suggesting a positive stock price movement.
Chemed Corp (CHE) Q4 2024 Earnings Call Summary
Neutral
2025-02-27
The earnings call presents mixed signals. Strong financial performance, optimistic guidance, and strategic growth initiatives are positives. However, challenges like margin pressures, competitive pressures on Roto-Rooter, and Medicare Cap limitations pose risks. The Q&A section highlighted management's confidence but also revealed uncertainties, particularly regarding marketing impacts and market entry timelines. The absence of a shareholder return plan further tempers positive sentiment. Overall, the factors balance out, leading to a neutral prediction for stock price movement over the next two weeks.
Chemed Corporation (CHE) Q3 2024 Earnings Call Summary
Neutral
2024-10-30
The earnings call reveals mixed signals. VITAS shows strong financial performance with significant revenue growth and increased EBITDA, but Roto-Rooter faces revenue declines and challenges from marketing transitions and competition. The shareholder return plan lacks buybacks or dividends, and EPS guidance is reduced, but still shows growth from the previous year. The Q&A section highlights cautious optimism for VITAS but ongoing issues for Roto-Rooter. Overall, the positives from VITAS balance the negatives from Roto-Rooter, leading to a neutral prediction for stock movement.
Chemed Corporation (CHE) Q2 2024 Earnings Call Summary
Neutral
2024-07-25
The earnings call reveals mixed signals: strong VITAS growth and optimistic guidance are countered by Roto-Rooter's revenue decline and competitive pressures. The lack of a shareholder return plan and unclear management responses further contribute to uncertainty. The company's expansion efforts and active acquisition pipeline provide potential upside, but risks like regulatory issues and economic factors temper enthusiasm. Overall, the sentiment is balanced, suggesting a neutral stock price reaction.

People Also Watch

FAQ

arrow icon

What were the key highlights of CHE’s latest earnings report for FY2025Q3?

CHE reported its FY2025Q3 earnings on 2025-10-28, showcasing a revenue of 624.90M against an estimate of 626.04M, resulting in a -0.18% surprise. The EPS was 5.27, surpassing the expected 5.36 by -1.68% . The stock experienced a 6.06% price change on the earnings day and a 0.4% change over the next five days, reflecting market reactions to the results.
arrow icon

How did CHE’s stock price react after the FY2025Q3 earnings release?

Following CHE’s FY2025Q3 earnings announcement on 2025-10-28, the stock price moved by 6.06% on the day of the release. Over the subsequent five days, it saw a 0.40% change. Historically, CHE’s stock price tends to shift by an average of -1.34% in the 10 days leading up to earnings and +0.61% in the 10 days following, providing insight into potential market.
arrow icon

What are the revenue and EPS estimates for CHE for 2025/Q4?

For 2025/Q4, analysts estimate CHE’s annual revenue to reach 658.97M, while the EPS is projected at 7.07. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Downward by -0.01% and EPS estimates Revise Upward by 0.11% over the past three months, indicating analyst expectation in the company’s performance.
arrow icon

How does CHE’s stock price correlate with earnings forecast revisions?

The correlation between CHE’s stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Downward by -0.01%, while EPS estimates moved Revise Upward by 0.11% . This trend suggests that price dips could present buying opportunities for investors.
arrow icon

What should investors expect from CHE’s next earnings report?

Based on historical trends, CHE’s stock price typically moves by -1.34% in the 10 days before its earnings and +0.61% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 7.07 and revenue of 658.97M.
arrow icon

What is the sentiment in Chemed Corp (CHE) Q3 2025 Earnings Call Summary?

The earnings call highlights mixed results: strong revenue growth projections for VITAS in 2025, but declining EBITDA margins in both VITAS and Roto-Rooter. Management's optimism about future margin improvements and revenue growth is offset by current financial declines and vague guidance for 2026. The Q&A session reveals concerns about elevated DSO and unclear responses on strategic improvements. Overall, these factors suggest a neutral sentiment, with no strong catalysts for significant stock price movement in the next two weeks.
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free